anti-CD19 + anti-CD22 TCR T-cell therapy (Eureka Therapeutics)

N/A

Report date: 2025/01/26 16:20:07

Base Information

Drug Nameanti-CD19 + anti-CD22 TCR T-cell therapy (Eureka Therapeutics)

Drug Alias Namedual anti-CD19/anti-CD22 TCR gamma delta T-cell therapy (Eureka Therapeutics)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsCD22 modulators

TargetsB-lymphocyte antigen CD19CD22

Therapy Area/IndicationsLymphoma, B-CellLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesEureka Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesEureka Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellLeukemia

Inactive IndicationsN/A

Other Information

ATC CodeN/A